Literature DB >> 27786606

Bispecific antibodies for viral immunotherapy.

Elisabeth K Nyakatura1, Alexandra Y Soare1, Jonathan R Lai1.   

Abstract

Bispecific antibody engineering, in which binding specificities toward 2 distinct epitopes are combined into a single molecule, can greatly enhance immunotherapeutic properties of monoclonal antibodies. While the bispecific antibody approach has been applied widely to targets for indications such as cancer and inflammation, the development of such agents for viral immunotherapy is only now emerging. Here, we review recent advances in the development of bispecific antibodies for viral immunotherapy, highlighting promising in vitro and in vivo results.

Entities:  

Keywords:  antibody engineering; antibody therapeutics; antiviral; bifunctional antibodies; bispecific antibodies; immunotherapy; passive immunization; virology

Mesh：

Substances：

Year:  2016        PMID： 27786606      PMCID： PMC5425146          DOI： 10.1080/21645515.2016.1251536

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  43 in total

1.  Stability engineering of scFvs for the development of bispecific and multivalent antibodies.

Authors:  Brian R Miller; Stephen J Demarest; Alexey Lugovskoy; Flora Huang; Xiufeng Wu; William B Snyder; Lisa J Croner; Norman Wang; Aldo Amatucci; Jennifer S Michaelson; Scott M Glaser
Journal:  Protein Eng Des Sel       Date:  2010-05-10       Impact factor: 1.650

2.  Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.

Authors:  Thomas Spreter Von Kreudenstein; Eric Escobar-Carbrera; Paula I Lario; Igor D'Angelo; Karine Brault; John Kelly; Yves Durocher; Jason Baardsnes; R Jeremy Woods; Michael Hongwei Xie; Pierre-Alain Girod; Michael D L Suits; Martin J Boulanger; David K Y Poon; Gordon Y K Ng; Surjit B Dixit
Journal:  MAbs       Date:  2013-07-08       Impact factor: 5.857

3.  A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion.

Authors:  Xin Shi; Yongqiang Deng; Huajing Wang; Guanghui Ji; Wenlong Tan; Tao Jiang; Xiaofeng Li; Hui Zhao; Tian Xia; Yanchun Meng; Chao Wang; Xiaojie Yu; Yang Yang; Bohua Li; E-De Qin; Jianxin Dai; Cheng-Feng Qin; Yajun Guo
Journal:  MAbs       Date:  2016-02-23       Impact factor: 5.857

4.  Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity.

Authors:  Koen Wagner; Mark J Kwakkenbos; Yvonne B Claassen; Kelly Maijoor; Martino Böhne; Koenraad F van der Sluijs; Martin D Witte; Diana J van Zoelen; Lisette A Cornelissen; Tim Beaumont; Arjen Q Bakker; Hidde L Ploegh; Hergen Spits
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-10       Impact factor: 11.205

5.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Authors:  Marina Caskey; Florian Klein; Julio C C Lorenzi; Michael S Seaman; Anthony P West; Noreen Buckley; Gisela Kremer; Lilian Nogueira; Malte Braunschweig; Johannes F Scheid; Joshua A Horwitz; Irina Shimeliovich; Sivan Ben-Avraham; Maggi Witmer-Pack; Martin Platten; Clara Lehmann; Leah A Burke; Thomas Hawthorne; Robert J Gorelick; Bruce D Walker; Tibor Keler; Roy M Gulick; Gerd Fätkenheuer; Sarah J Schlesinger; Michel C Nussenzweig
Journal:  Nature       Date:  2015-04-08       Impact factor: 49.962

6.  An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection.

Authors:  Mark Zanin; Zhen-Yong Keck; G Jonah Rainey; Chia-Ying Kao Lam; Adrianus C M Boon; Adam Rubrum; Daniel Darnell; Sook-San Wong; Yolanda Griffin; Jinming Xia; Robert G Webster; Richard Webby; Syd Johnson; Steven Foung
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

Review 7.  Engineering broadly neutralizing antibodies for HIV prevention and therapy.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Adv Drug Deliv Rev       Date:  2016-01-29       Impact factor: 15.470

8.  Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules.

Authors:  Anna Hultberg; Nigel J Temperton; Valérie Rosseels; Mireille Koenders; Maria Gonzalez-Pajuelo; Bert Schepens; Lorena Itatí Ibañez; Peter Vanlandschoot; Joris Schillemans; Michael Saunders; Robin A Weiss; Xavier Saelens; José A Melero; C Theo Verrips; Steven Van Gucht; Hans J de Haard
Journal:  PLoS One       Date:  2011-04-01       Impact factor: 3.240

9.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962
View more
  8 in total

1.  Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.

Authors:  Elisabeth K Nyakatura; Samantha E Zak; Anna Z Wec; Daniel Hofmann; Sergey Shulenin; Russell R Bakken; M Javad Aman; Kartik Chandran; John M Dye; Jonathan R Lai
Journal:  J Biol Chem       Date:  2018-03-02       Impact factor: 5.157

Review 2.  Bispecific antibodies: Potential immunotherapies for HIV treatment.

Authors:  Giulia Fabozzi; Amarendra Pegu; Richard A Koup; Constantinos Petrovas
Journal:  Methods       Date:  2018-10-22       Impact factor: 3.608

Review 3.  Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow.

Authors:  Raoufeh Ahamadi-Fesharaki; Abolfazl Fateh; Farzam Vaziri; Ghasem Solgi; Seyed Davar Siadat; Fereidoun Mahboudi; Fatemeh Rahimi-Jamnani
Journal:  Mol Ther Oncolytics       Date:  2019-03-23       Impact factor: 7.200

Review 4.  Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation.

Authors:  Karlijn van der Straten; Marit J van Gils; Steven W de Taeye; Godelieve J de Bree
Journal:  Front Med Technol       Date:  2022-03-28

5.  Directing HIV-1 for degradation by non-target cells, using bi-specific single-chain llama antibodies.

Authors:  Jord C Stam; Steven de Maat; Dorien de Jong; Mathia Arens; Fenna van Lint; Lavina Gharu; Mark H van Roosmalen; Rob C Roovers; Nika M Strokappe; Ralf Wagner; Alexander Kliche; Hans J de Haard; Paul M van Bergen En Henegouwen; Monique Nijhuis; C Theo Verrips
Journal:  Sci Rep       Date:  2022-08-04       Impact factor: 4.996

6.  Fab-Arm Exchange Combined with Selective Protein A Purification Results in a Platform for Rapid Preparation of Monovalent Bispecific Antibodies Directly from Culture Media.

Authors:  James Steinhardt; Yanli Wu; Ryan Fleming; Ben T Ruddle; Pooja Patel; Herren Wu; Changshou Gao; Nazzareno Dimasi
Journal:  Pharmaceutics       Date:  2019-12-18       Impact factor: 6.321

7.  Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.

Authors:  Jong Shin; Paul J Phelan; Ole Gjoerup; William Bachovchin; Peter A Bullock
Journal:  Protein Expr Purif       Date:  2020-09-25       Impact factor: 1.650

8.  Development and immunobiological evaluation of nanoparticles containing an immunodominant epitope of herpes simplex virus.

Authors:  Gabriel M Hilario; Fernando B Sulczewski; Raquel Liszbinski; Larissa D Mello; Gustavo Hagen; Tiago Fazolo; Jayme Neto; Eliane Dallegrave; Pedro Romão; Tanira Aguirre; Luiz C Rodrigues Junior
Journal:  IET Nanobiotechnol       Date:  2021-03-30       Impact factor: 2.050
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.